Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Preferred Dividend Payments (2016)

Iovance Biotherapeutics has reported Preferred Dividend Payments over the past 2 years, most recently at $49.5 million for Q3 2016.

  • Quarterly results put Preferred Dividend Payments at $49.5 million for Q3 2016, changed N/A from a year ago — trailing twelve months through Dec 2017 was $49.5 million (changed 0.0% YoY), and the annual figure for FY2016 was $49.5 million, changed.
  • Preferred Dividend Payments for Q3 2016 was $49.5 million at Iovance Biotherapeutics, up from -$8.5 million in the prior quarter.
  • Over the last five years, Preferred Dividend Payments for IOVA hit a ceiling of $49.5 million in Q3 2016 and a floor of -$8.5 million in Q4 2013.